Labs / CDMO: development & manufacturing
Nitto Avecia
Milford, MA, United States · avecia.com
GMP · FDA registered
Nitto Avecia develops and manufactures oligonucleotide therapeutics for pharmaceutical companies, from preclinical work through commercial supply. It operates facilities in Milford, Massachusetts, and Cincinnati, Ohio, serving customers with development, manufacturing, analytical, and quality support.
They take quote requests through a form on their website with project details. Their quote form
What they offer
Preclinical Manufacturing
Provides custom preclinical oligonucleotide manufacturing through the OliGrow® service for non-cGMP applications.
Analytical Development
Develops, qualifies, and validates analytical methods for raw materials, intermediates, and final product, including support for ICH stability studies.
Process Development
Develops and validates oligonucleotide processes and supports onboarding risk assessments, scale-up, specification development, and raw material qualification.
Drug Substance Manufacturing
Manufactures oligonucleotide drug substance from preclinical quantities to commercial supply.
Process Performance Qualification
Develops and executes PPQ programs for oligonucleotide manufacturing.
Quality Control/Stability
Provides study design, comprehensive testing services, and sample storage conditions for quality control and stability work.
What they work on
- Modalities
- Oligonucleotide, Gene editing
- Assays and studies
- analytical method development, method transfer, method validation, stability studies, impurity testing, sequencing, environmental monitoring, raw material analysis, in-process analysis, final product analysis
- Instruments and platforms
- LC-ESI-MS/MS, HRAMS
- Scale and capacity
- batch sizes from 100 mg to 25 g, batches from a few mmol up to 1600 mmol, first 50 mg of preclinical material, hundreds of kilograms in commercial supply, multiple cGMP manufacturing trains, ISO8-qualified, HEPA-filtered manufacturing suites
- Turnaround
- fast turnaround times
- Type
- CRDMO
- Sites
- Milford, United States · Cincinnati, United States
- Quality
- FDA-inspected · GMP-compliant · cGMP requirements of 21 CFR Part 210 and · ICH Q7 · EU Current Good Manufacturing Practice f · FDA-registered facilities · Successful track record of FDA and QP in · Most recent FDA inspection in August 202 (Cincinnati facility)
- Serves
- global
- Address
- 125 Fortune Boulevard Milford, MA 01757
Public records
- FDA establishment
- 3000215431
- FDA drug establishment
- Nitto Denko Avecia Inc. source
- Vice President of Business Development & Project Manag
- Management Craig Dobbs on their site
- FDA drug establishment registration
- 3000215431 · API MANUFACTURE source
Similar labs. Alcami, Minaris, Porton, WuXi STA
Found in a contract services directory. Listing built from avecia.com. Work here? Claim this listing.